- The AAN announced new guidelines for treating MS.
- A new study will convince you to begin MS disease-modifying therapy sooner, rather than later.
- The National MS Society has announced $14.2 million dollars in funding for 45 new research projects aimed at slowing, stopping, and ending MS.
- Genentech announced some good news for MS patients taking Ocrevus.
- Biogen announced the results of several MS research studies.
- Computer-based cognitive training can improve memory for people living with MS.
My guest on the podcast is 3-time Stanley Cup winner and and star of the National Hockey League's Chicago Blackhawks, Bryan Bickell. Bryan retired from hockey last year, after being diagnosed with MS.
We'll talk with Bryan about what it was like to get that diagnosis, what it was like to score that very memorable final goal of his career, and what lies ahead for him. (NOTE: During our conversation, Bryan references a website as “My Fighting Hockey Story”. The correct website is MyFightingStory.com. Sorry for any confusion!)
AAN Announces New Treatment Guidelines For MS 2:02
Study Indicates Importance of Starting MS Treatment ASAP 4:01
National MS Society Investing $14.2 Million in New Research 6:54
Genentech Has Good News For MS Patients Taking Ocrevus 8:25
Biogen Study Correlates MS Cognitive Decline to Socioeconomic Demographics 10:35
Computer-Based Cognitive Training Improves Memory for People Living with MS 12:49
The MSUnderstood Cafe Gives People A Taste of MS 13:49
Interview with hockey star Bryan Bickell 16:03
If your podcast app doesn't show these links, you'll find them in the show notes at www.RealTalkMS.com
RealTalk MS Episode 29
Guest: Bryan Bickell
Hosted By: Jon Strum
Tags: MS, multiple sclerosis, AAN, AANAM, MS Treatment Guidelines, Genentech, Biogen, Ocrevus, NMSS, National MS Society, Roche, MSUnderstood Cafe, Bryan Bickell, RealTalkMS